Drug Profile

KLK2 directed T cell engager therapeutic - EpimAb Biotherapeutics/Juri Biosciences

Alternative Names: EM-1031

Latest Information Update: 13 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EpimAb Biotherapeutics
Developer EpimAb Biotherapeutics; Juri Biosciences
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Prostate cancer

Most Recent Events

27 May 2025 KLK2 directed T cell engager licensed to Juri Biosciences worldwide
27 May 2025 Early research in Prostate cancer in China (Parenteral)
25 Apr 2025 Preclinical trials in Prostate cancer in China (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com